Johnson & Johnson Total Liabilities 2012-2026 | JNJ
Johnson & Johnson total liabilities from 2012 to 2026. Total liabilities can be defined as the total value of all possible claims against the corporation.
- Johnson & Johnson total liabilities for the quarter ending March 31, 2026 were $117.666B, a 8.33% increase year-over-year.
- Johnson & Johnson total liabilities for 2025 were $117.666B, a 8.33% increase from 2024.
- Johnson & Johnson total liabilities for 2024 were $108.614B, a 9.95% increase from 2023.
- Johnson & Johnson total liabilities for 2023 were $98.784B, a 10.66% decline from 2022.
|
Johnson & Johnson Annual Total Liabilities (Millions of US $) |
|
|---|---|
| 2025 | $117,666 |
| 2024 | $108,614 |
| 2023 | $98,784 |
| 2022 | $110,574 |
| 2021 | $107,995 |
| 2020 | $111,616 |
| 2019 | $98,257 |
| 2018 | $93,202 |
| 2017 | $97,143 |
| 2016 | $70,790 |
| 2015 | $62,261 |
| 2014 | $60,606 |
| 2013 | $58,630 |
| 2012 | $56,521 |
| 2011 | $56,564 |
|
Johnson & Johnson Quarterly Total Liabilities (Millions of US $) |
|
|---|---|
| 2025-12-31 | $117,666 |
| 2025-09-30 | $113,539 |
| 2025-06-30 | $114,916 |
| 2025-03-31 | $115,562 |
| 2024-12-31 | $108,614 |
| 2024-09-30 | $108,129 |
| 2024-06-30 | $109,550 |
| 2024-03-31 | $101,946 |
| 2023-12-31 | $98,784 |
| 2023-09-30 | $94,833 |
| 2023-06-30 | $115,277 |
| 2023-03-31 | $125,100 |
| 2022-12-31 | $110,574 |
| 2022-09-30 | $100,525 |
| 2022-06-30 | $101,367 |
| 2022-03-31 | $103,646 |
| 2021-12-31 | $107,995 |
| 2021-09-30 | $108,956 |
| 2021-06-30 | $106,860 |
| 2021-03-31 | $106,723 |
| 2020-12-31 | $111,616 |
| 2020-09-30 | $106,220 |
| 2020-06-30 | $95,402 |
| 2020-03-31 | $93,723 |
| 2019-12-31 | $98,257 |
| 2019-09-30 | $97,311 |
| 2019-06-30 | $94,332 |
| 2019-03-31 | $91,072 |
| 2018-12-31 | $93,202 |
| 2018-09-30 | $91,077 |
| 2018-06-30 | $92,476 |
| 2018-03-31 | $93,370 |
| 2017-12-31 | $97,143 |
| 2017-09-30 | $81,679 |
| 2017-06-30 | $80,885 |
| 2017-03-31 | $74,577 |
| 2016-12-31 | $70,790 |
| 2016-09-30 | $67,600 |
| 2016-06-30 | $67,341 |
| 2016-03-31 | $63,584 |
| 2015-12-31 | $62,261 |
| 2015-09-30 | $61,712 |
| 2015-06-30 | $60,905 |
| 2015-03-31 | $60,712 |
| 2014-12-31 | $60,606 |
| 2014-09-30 | $55,506 |
| 2014-06-30 | $57,152 |
| 2014-03-31 | $56,748 |
| 2013-12-31 | $58,630 |
| 2013-09-30 | $57,129 |
| 2013-06-30 | $54,660 |
| 2013-03-31 | $54,681 |
| 2012-12-31 | $56,521 |
| 2012-09-30 | $55,190 |
| 2012-06-30 | $55,316 |
| 2012-03-31 | $54,828 |
| 2011-12-31 | $56,564 |
| 2011-09-30 | $50,294 |
| 2011-06-30 | $49,982 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |